Bone Tumor Treatment — Cost, Top Hospitals & Success Rates | MyMedicPlus

Bone tumours encompass a spectrum of primary bone neoplasms arising from bone and its constituent cells (osteoblasts, chondroblasts, osteoclasts, and bone marrow stromal cells) and secondary tumours from metastatic spread of carcinomas to bone. Primary malignant bone tumours are rare, constituting less than 1% of all cancers, with approximately 3,400 new cases diagnosed per year in the US. The three most common primary bone malignancies are osteosarcoma (most common in adolescents and young adults, arising predominantly around the knee), Ewing's sarcoma (second most common, found predominantly in the diaphysis of long bones and flat bones), and chondrosarcoma (most common in adults over 40, arising from cartilage).

Treatment of primary bone malignancies is a multidisciplinary endeavour requiring input from orthopaedic oncological surgeons, medical oncologists, radiation oncologists, pathologists, radiologists, and rehabilitation specialists, all discussed at a specialised sarcoma multidisciplinary team (MDT) meeting. The treatment paradigm for osteosarcoma and Ewing's sarcoma — the two most common chemotherapy-sensitive primary bone tumours — involves neoadjuvant (pre-operative) chemotherapy to reduce tumour volume and treat micrometastatic disease, followed by surgical resection with wide margins, followed by adjuvant chemotherapy to complete the systemic treatment. Limb-sparing surgery — removal of the tumour with wide margins and skeletal reconstruction using endoprosthetic replacement, allograft, or vascularised fibula — has replaced amputation as the primary surgical approach in approximately 85–90% of appropriately selected cases, without compromising survival.

Osteosarcoma is the most common primary bone malignancy in children and young adults, with peak incidence at 15–19 years, and a second peak in older adults (>65) associated with Paget's disease or prior radiotherapy. It most frequently affects the distal femur, proximal tibia, and proximal humerus — bones that are most metabolically active during the pubertal growth spurt. Osteosarcoma is classified as high-grade (conventional osteosarcoma — osteoblastic, chondroblastic, fibroblastic subtypes) or low-grade (parosteal, periosteal), with high-grade disease requiring chemotherapy.

Ewing's sarcoma affects young patients (5–25 years predominantly) and characteristically involves the midshaft of long bones (femur, humerus, fibula) and flat bones (pelvis, ribs). It is defined molecularly by the EWSR1-FLI1 (or variant) translocation. Chondrosarcoma is predominantly an adult tumour, chemotherapy-resistant, and treated primarily with surgery. Metastatic bone disease from breast, prostate, lung, kidney, and thyroid cancers is far more common than primary bone cancer; it causes bone pain, pathological fractures, and hypercalcaemia, managed with bisphosphonates/denosumab, radiotherapy, orthopaedic fixation, and systemic cancer treatment.

All patients with suspected primary bone malignancy should be referred to a specialist orthopaedic oncology/sarcoma centre before any biopsy or surgical intervention, as inappropriate surgery at non-specialist centres can compromise limb-sparing surgery eligibility and worsen outcomes. Core needle biopsy under image guidance (CT or ultrasound) provides tissue diagnosis with minimal surgical trauma and no compromise of subsequent surgical plans.

Limb-sparing surgery eligibility depends on tumour location, extent, involvement of neurovascular structures, and response to neoadjuvant chemotherapy. Most patients with localised osteosarcoma and Ewing's sarcoma around the knee or proximal humerus are limb-sparing candidates; involvement of the major neurovascular bundle (popliteal vessels and sciatic nerve at the knee) may necessitate amputation to achieve clear margins. Patients with pulmonary metastases at presentation (approximately 15–20% of osteosarcoma) receive the same treatment with curative intent — complete surgical resection of both primary and pulmonary metastases achieves long-term survival in approximately 30–40% of these patients.

For osteosarcoma and Ewing's sarcoma, the standard treatment paradigm is: neoadjuvant chemotherapy (10–16 weeks pre-operatively), followed by definitive surgery, followed by adjuvant chemotherapy (16–20 additional weeks). Osteosarcoma chemotherapy uses MAP regimen (methotrexate, doxorubicin/adriamycin, cisplatin) or EURAMOS/COSS-86 variants. Ewing's sarcoma uses VIDE (vincristine, ifosfamide, doxorubicin, etoposide) or VAIA/COSS-based protocols. Histological response to neoadjuvant chemotherapy — specifically the percentage of tumour necrosis in the resection specimen — is a major prognostic factor (>90% necrosis is favourable response).

Surgical options for limb-sparing resection include endoprosthetic replacement (expanding modular prostheses in growing children, standard prostheses in adults), biological reconstruction (intercalary allograft, vascularised fibula, allograft-prosthesis composites), and rotationplasty — a unique procedure for distal femur tumours in children where the lower leg is rotated 180 degrees and reattached, with the ankle functioning as a knee joint, enabling highly functional prosthetic limb fitting. For Ewing's sarcoma in certain flat bone locations (pelvis, vertebra), high-dose conformal radiotherapy (54–60 Gy) may replace or supplement surgery where wide surgical margins cannot be achieved. Targeted therapies play an increasing role: denosumab (anti-RANKL monoclonal antibody) is used for giant cell tumour of bone and to reduce skeletal-related events in metastatic disease; mTOR inhibitors are active in osteosarcoma relapse; ALK inhibitors for ALK-rearranged tumours. Proton beam therapy offers superior dose conformality for skull base and sacral tumours where conventional photon therapy risks unacceptable neurological injury.

Modern multimodal treatment of osteosarcoma achieves 5-year overall survival of approximately 65–70% for localised disease — a dramatic improvement from the pre-chemotherapy era when the 5-year survival was below 20%. For Ewing's sarcoma, 5-year survival for localised disease is approximately 60–70% with combined modality treatment. Limb-sparing surgery, when oncologically sound, achieves equivalent survival to amputation while preserving a functional limb — the major advance in bone tumour surgery over the past 30 years.

Endoprosthetic replacements in limb-sparing surgery provide immediate weight-bearing and functional recovery. Expandable prostheses in growing children allow prosthesis lengthening as the child grows, avoiding the functional discrepancy of fixed-length implants. Patients achieving complete histological remission after neoadjuvant chemotherapy have significantly better long-term survival, validating the neoadjuvant approach for both biological and surgical reasons (smaller, better-delineated tumour at surgery). High-volume specialist sarcoma centres demonstrate superior outcomes compared with low-volume centres, underscoring the importance of referral to specialist units.

Chemotherapy toxicities specific to bone tumour regimens include: high-dose methotrexate causing mucositis, hepatotoxicity, and nephrotoxicity (requiring leucovorin rescue and aggressive hydration); doxorubicin cumulative cardiotoxicity (requiring surveillance echocardiography during treatment — lifetime maximum dose applies); cisplatin nephrotoxicity and ototoxicity (hearing loss in 15–30% of high-dose cisplatin-treated patients); and ifosfamide nephrotoxicity (Fanconi syndrome) and urotoxicity (haemorrhagic cystitis, prevented by mesna and hyperhydration). Long-term fertility effects of chemotherapy in young patients are important — sperm banking and oocyte cryopreservation should be discussed before treatment commencement.

Surgical complications of limb-sparing resection and endoprosthetic replacement include: periprosthetic infection (5–10% lifetime risk — catastrophic as it often requires prosthesis removal and revision); implant loosening or fracture requiring revision surgery; local tumour recurrence (5–10% overall risk — the most feared surgical outcome); wound complications; and nerve injury affecting limb function. Amputation, when required, carries well-described rehabilitation challenges but modern prosthetic limb technology enables most patients to achieve functional ambulation and return to sports.

Surveillance after primary bone tumour treatment consists of regular clinical assessment, radiological imaging (chest CT for pulmonary metastasis surveillance every 3 months for 2 years, then 6-monthly for 3 more years), and local imaging of the surgical site (MRI or X-ray every 3–6 months for 5 years). Local recurrence is managed with re-excision at specialist centres, potentially with amputation if wide margins cannot be achieved. Pulmonary metastases are approached with aggressive surgical resection (thoracotomy) when technically feasible.

Functional rehabilitation after limb-sparing surgery includes physiotherapy from the early post-operative period with progressive weight-bearing, strengthening exercises, and gait retraining. Return to sporting activity is assessed individually based on reconstruction type and chemotherapy completion. Cardiology surveillance for anthracycline cardiotoxicity, audiology monitoring for cisplatin ototoxicity, and renal function monitoring for cisplatin and ifosfamide nephrotoxicity continue in the survivorship phase.

Bone tumour treatment is one of the more expensive cancer treatment episodes, reflecting the complexity of multimodal therapy, specialist surgical expertise, costly endoprosthetic implants, and prolonged chemotherapy. In the United States, total treatment cost for osteosarcoma (chemotherapy + limb-sparing surgery + adjuvant chemotherapy) ranges from USD 150,000–400,000 or more. Endoprosthetic implants alone cost USD 30,000–80,000 depending on design complexity. In the UK, all NHS cancer treatment is covered.

India has established internationally recognised sarcoma treatment programmes, most notably at Tata Memorial Hospital Mumbai (one of the world's highest-volume bone tumour programmes), AIIMS, and Apollo Hospitals. Total treatment costs for osteosarcoma or Ewing's sarcoma at Tata Memorial — including neoadjuvant chemotherapy, limb-sparing surgery with endoprosthesis, and adjuvant chemotherapy — are approximately USD 15,000–40,000, representing savings of 75–85% versus US costs. The endoprosthetic implants used are major international brands (Stryker, Zimmer TMTT, Link). Thailand and Turkey are further destinations for bone tumour surgery.

For low-grade chondrosarcomas, wide surgical excision alone (without chemotherapy) is the standard treatment, as chondrosarcoma is chemotherapy-resistant. For bone metastases from solid tumours, treatment is primarily directed at the underlying cancer (systemic chemotherapy, targeted therapy, immunotherapy) with adjunctive bone-specific treatments: bisphosphonates (zoledronic acid) or denosumab (RANK-L inhibitor) reduce skeletal-related events (pathological fractures, cord compression) and are the standard of care for bone metastatic disease in breast, prostate, and lung cancer.

Radiotherapy alone is used for bone metastases causing pain that do not require stabilisation, achieving significant pain relief in approximately 60–75% of cases. Stereotactic body radiotherapy (SBRT) to oligometastatic bone deposits achieves local control of 80–90% and is increasingly used for both primary and metastatic bone lesions with excellent precision and tolerability. Palliative orthopaedic surgery — prophylactic intramedullary nail insertion for impending pathological fractures — prevents the morbidity of fracture in patients with bone metastases and is an important quality-of-life intervention even in patients with systemic metastatic disease.